RE:Interesting game of "chicken" going on here..Hi ronrydell.
I'm sure the finacing will happen. There is no doubt in my mind at all. The question is how.
And the answer to that question will tell us a lot of important information IMHO;
- Will Don be able to bring in a new regional partner with significant geographical clout like Hepalink already has?
- If so, will it create a new dimension of shared power and shared risk?
- Will RVX find a partner whose intellectual development will complement their BETi approach? Keep in mind Ms Norma Biln was appointed to the board. Check out her CV on the RVX website.
- With CD Venture holding 4.3% of the shares might something happen with Boehringer Ingelheim in Europe or on a broader geographic basis? Are they willing to come up to Hepalink levels (but at a price adjusted to current developments)?
- Some of the testing for BoM is happeing in South America. Might that lead to opportunities?
So I think Don Has lots of room to play out his chess game to his companies advantage.
One assumption I've made is that Eastern and NGN are in this purely for capital gain. However, this could be very wrong. Perhaps with the right conditions one or the other could move in for control.
One thing I am very curious about. In all of my research in the epigenetic area (not extensive by any means) it does not appear that any company is even evident in terms of the CVD and CKD areas that RVX is addressing with apabetalone. Now that is not really true in terms of indications, but the approaches that have been discussed on various boards do not seem to relate directly to the particular BET inhibition that RVX has discovered. Why? Why doesn't BP just copy? Do they not believe the post hoc findings? If they are not copying is it because they don't know about apabetalone (they should know now with the apabetalone + rosuvastatin patent)? We see that RVX shares their discoveries at scientific and investment conferences constantly so it can't be a lack of awareness at that level.
Isn't it odd that BP can buy the molecule (apabetalone) and experiment with it. Perhaps they have?
Just some rambling thoughts. I am very excited to hear about the next financing. It should be interesting.
GLTA
Toinv